Liraglutide (Victoza, Saxenda) and cannabis — GLP-1 receptor agonist interaction profile covering gastric delay, edible timing, and GI side effect overlap.
Victoza (liraglutide, type 2 diabetes)Saxenda (liraglutide, weight management)+Cannabis / THC
⚠️
Caution Advised
Liraglutide + Cannabis (THC/CBD)
No published clinical trials have studied liraglutide and cannabis together. GLP-1 receptor activation delays gastric emptying, creating the same edible-timing unpredictability seen with other GLP-1 medications. Discuss with your prescriber.
What This Means
In Plain Language
Liraglutide is a GLP-1 receptor agonist administered by daily subcutaneous injection. Like semaglutide, it delays gastric emptying, which creates edible cannabis absorption timing concerns. The combination has not been formally studied. No FDA prescribing information for Victoza or Saxenda mentions cannabis as a contraindication, but this reflects the absence of data, not confirmed safety.
Clinical Considerations
Key Risks & Factors
Gastric emptying delay and edible timing: Liraglutide delays gastric emptying, potentially slowing edible cannabis absorption and increasing risk of delayed, unexpectedly intense effects.
Additive GI effects: Both liraglutide and cannabis can cause nausea. Combined use during Saxenda or Victoza titration may worsen GI side effects.
Appetite signal interaction: THC may stimulate appetite while liraglutide (Saxenda) suppresses it for weight management. This pharmacological conflict may reduce Saxenda's efficacy in some patients.
No clinical trial data: Zero published studies exist on liraglutide and cannabis co-administration.
Conservative Safety Assessment
Liraglutide shares the same GLP-1 mechanism as semaglutide, and the theoretical cannabis interaction concerns are similar — primarily edible timing unpredictability and additive GI effects. This 'Caution Advised' rating reflects the absence of clinical trial data. Reviewed and audited by Sanford A. Orloff, RPh (ret).
Enter all your medications, supplements, and lifestyle substances to see a complete pharmacist-reviewed interaction report — free, no account required.
Pharmacist-reviewed · FDA & NIH sources only · Always free
👨⚕️
Sanford A. Orloff, RPh (ret)
Registered Pharmacist · 40+ Years Clinical Experience · NPI 1518289974
Every interaction profile on InteractSafe is reviewed for editorial accuracy by a retired pharmacist with over 40 years of clinical experience in medication therapy management, patient counseling, and pharmaceutical care.
No clinical trial has studied this combination. As a GLP-1 receptor agonist, liraglutide delays gastric emptying, which affects edible cannabis absorption timing. Discuss cannabis use with your prescribing physician, particularly if you use edibles or are in the titration phase.
THC stimulates appetite through CB1 receptors, which may partially counteract Saxenda's appetite-suppressing effect in some patients. There is no clinical trial measuring this interaction, but the pharmacological conflict is theoretically plausible for regular THC users.
This profile is for educational purposes only. Reviewed for editorial accuracy by Sanford A. Orloff, RPh (ret).
It is NOT medical advice and does not replace consultation with a licensed physician or pharmacist.
Never change your medication routine based on this information alone.
Read Full Safety Terms →